經皮藥物給藥：技術・市場・企業

經皮藥物給藥：技術・市場・企業 是由出版商Jain Pharmabiotech在2012年04月所出版的。 這份英文市場調查報告書價格從美金3000起跳。

簡介

本報告書內容包括：各種經皮藥物給藥的技術及相關市場的調查、及相關企業的資訊、內容綱要摘記如下：

目錄

• 實施摘要
• 經皮藥物給藥的基礎
• 經皮藥物給藥技術
• 經皮治療
• 經皮藥物給藥的市場
• 經皮藥物給藥的相關企業
• 參考

目錄

Abstract

Benefits of this report

• Up-to-date one-stop information on transdermal drug delivery
• Description of 131 companies involved and 110 collaborations in this area
• Market analysis 2011-2021/
• Market values in major regions
• Strategies for developing markets for transdermal drug delivery
• A selected bibliography of 200 publications
• Text is supplemented by 18 tables and 10 figures

Who should read this report?

• Biotechnology companies developing transdermal technologies
• Drug delivery companies
• Pharmaceutical companies interested in transdermal drug delivery
• Pharmaceutical research institutes

Summary

This report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral,intravascular, subcutaneous and transmucosal routes. Various transdermal drug delivery technologies are described including the use of suitable formulations, carriers and penetration enhancers. The most commonly used transdermal system is the skin patch using various types of technologies. Nanoparticles as well as the use of physical agents to facilitate transcutaneous drug delivery is described. Microneedle and needleless technologies are also described. Transdermal technologies may be applied for several categories of pharmaceuticals used for the treatment of disorders of the skin or for systemic effect to treat diseases of other organs. Several transdermal products and applications include hormone replacement therapy, contraception, management of pain, angina pectoris, smoking cessation and neurological disorders such as Parkinson's disease. The market for transdermal drug delivery is analyzed according to technologies and therapeutic areas from 2011 to 2021. This market is analyzed according to geographical regions as well.

Table of Contents

0. Executive Summary 9

1. Basics of Transdermal Drug Delivery 11

• Introduction 11
• Historical landmarks in transdermal drug delivery 11
• Anatomy and physiology of skin 12
• Transcutaneous absorption 12
• Transdermal versus other methods of drug delivery 12
• Advantages of transdermal drug delivery 13
• First-Pass Effect 13
• Drawbacks of transdermal delivery 13
• Factors that influence transdermal drug delivery 13
• Events governing transcutaneous absorption 14
• Properties of the skin 14
• Properties of drugs 15
• The role of pH and pharmacokinetics 15
• Intradermal disposition of drugs after topical application 16

2. Transdermal Drug Delivery Technologies 17

• Introduction 17
• Local application formulations 18
• Crystalline topical formulations 18
• Microemulsions for transdermal drug delivery 18
• Nanoemulsions for transdermal drug delivery 19
• Transdermal gel technology 19
• Film forming polymeric solutions 20
• Biphasix system 21
• Penetration enhancers 21
• Chemical enhancers 21
• Nitric oxide-based transdermal drug delivery 23
• Vesicular transdermal carriers 23
• Liposomes 24
• Transfersomes 24
• Ethosomes 25
• Elastic vesicles for transdermal drug delivery 25
• Nanovesicles for transdermal drug delivery 26
• Transdermal patches 26
• Adhesives for transdermal patches 27
• Commercial development of transdermal patches 28
• Innovations in transdermal patches 29
• e-Patch"! controlled release micropump system 29
• Patchless Transdermal Delivery System 30
• Metered-dose transdermal system 30
• Use of physical modalities to facilitate transdermal transport 31
• Transdermal electrotransport 31
• Electroporation 31
• Drug delivery by electroporation 32
• Cryoelectrophoresis 33
• Iontophoresis 34
• Iontophoresis compared with electrophoresis 35
• Application of iontophoresis for drug delivery 35
• Companies with technologies for drug delivery by iontophoresis 36
• Combination of electrophoresis and iontophoresis 37
• Dermaportation 37
• Radiofrequency-driven transdermal delivery 37
• Microporation 38
• Transcutaneous drug delivery by electropulsation 38
• Companies involved in electroporation-based drug delivery 39
• Electrode Scanning System 39
• Use of electrostatic force in skin patch technology 39
• Multiple Absorption Kinetic System 40
• Transdermal drug delivery facilitated by heat 40
• Controlled, heat-aided drug delivery 40
• Ultrasound 41
• Magnetophoresis 43
• Use of lasers for transdermal drug delivery 43
• Transdermal drug delivery by laser-induced pressure waves 43
• Transdermal drug delivery by laser-assisted changes in skin 43
• Transdermal delivery by gas under pressure 44
• Transdermal delivery with PowderJect gas gun 44
• Microscission induced by gas 44
• Role of microelectronics in transdermal drug delivery 45
• Microneedles and dermal microinjection technologies 45
• Microneedle patch 46
• AdminPatchR microneedle array 47
• Biodegradable microneedles 47
• Ceramic microneedle arrays 48
• Dissolvable microneedle patches 48
• Microneedle arrays for drug delivery 48
• MicroPyramid"! microneedles 49
• Microstructured Transdermal Systems 49
• Microneedle Array Patch technology 50
• Microneedle transdermal chip 50
• Microneedle applicator device 51
• Nanoject"! microneedle technology 51
• Silk microneedles 51
• ZP Patch microprojections technology 52
• Companies developing microneedles for transdermal drug delivery 52
• Needlefree injections 53
• Glide SDIR solid dose injector 53
• Jet injection 53
• Mini-Ject needlefree delivery system 54
• MicroJet for painless injections 54
• Nanoliter-volume pulsed microjets 54
• SUMAVEL"! DosePro"! needle-less injection 55
• Skin ablation or abrasion for drug delivery 55
• Nanotechnology-based transdermal drug delivery 55
• Delivery of nanostructured drugs from transdermal patches 56
• Effect of mechanical flexion on penetration of bucky balls through the ski 56
• Nanoparticles and nanoemulsions for skin disorders 56
• Nanotechnology-based transdermal vaccination and immunotherapy 56
• NanoCyte transdermal drug delivery system 57
• Safety issues of applications of nanomaterial carriers on the skin 57
• Transdermal administration of lipid nanocapsules 58
• Transdermal nanoparticle preparations for systemic effect 58
• Comparison of transdermal drug delivery systems 59
• Transdermal drug design 59
• In vitro testing of transdermal drug delivery systems 59
• In vivo testing of drug delivery systems 60
• Infrared spectroscopy for evaluation of transdermal drug delivery 61
• Modeling of transport through the skin 61
• Concluding remarks on transdermal drug delivery technologies 62
• Future developments in transdermal drug delivery 62

3. Transdermal Therapeutics 65

• Introduction 65
• Drugs that can be administered transdermally 65
• Skin disorders 68
• Psoriasis 68
• Nanoemulsions for paclitaxel delivery in psoriasis 68
• Iontophoresis for treatment of psoriasis 68
• Hair loss 68
• Cardiovascular disorders 69
• Angina pectoris 69
• Transdermal drug delivery for hypertension 70
• Transdermal beta blockers 70
• Transdermal anticoagulants 71
• Congestive heart failure 71
• Respiratory diseases 71
• Asthma 71
• Chronic obstructive pulmonary disease 72
• Neurological and psychiatric disorders 72
• Parkinson's disease 72
• Transdermal drug delivery for Parkinson's disease 73
• Transdermal dopamine agonists for Parkinson's disease 73
• Rotigotine 74
• Transdermal administration of other drugs for Parkinson disease 76
• Depression 76
• Transdermal selegiline 76
• Bipolar disorder 77
• Transdermal lithium 77
• Restless legs syndrome 77
• Alzheimer's disease 77
• Transdermal nicotine for Tourette syndrome 78
• Attention deficit hyperactivity disorder 78
• Transdermal methylphenidate 79
• Migraine 79
• Transdermal lidocaine 79
• Transdermal sumatriptan 79
• Epilepsy 80
• Tinnitus/Vertigo 80
• Transdermal nitroglycerin for vasospasm due to subarachnoid hemorrhage 81
• Musculoskeletal disorders 81
• Osteoporosis 81
• Transdermal alendronate 81
• Transdermal estrogen 81
• Transdermal human parathyroid hormone 82
• Osteoarthritis 82
• Transdermal therapy of diabetes 82
• Transdermal insulin delivery in diabetes 82
• Transdermal GLP1 agonist 83
• Male sexual disorders 84
• Erectile dysfunction 84
• Topical and transdermal preparation for erectile dysfunction 84
• Hypogonadism in the male 84
• Topical testosterone 85
• Women's health 86
• Female sexual arousal disorder 86
• Menopause 87
• Hormone replacement therapy for menopause 87
• Effect of transdermal estradiol on bone density 89
• Transdermal PTH for postmenopausal osteoporosis 89
• Transdermal testosterone for low libido in postmenopausal women 89
• Breast disorders 90
• Dysmenorrhea 90
• Female infertility 90
• Contraception 91
• Female contraception 91
• Ortho Evra"! 91
• BAY86-5016 92
• Male contraception 92
• Transdermal progestin plus testosterone 92
• Cancer 93
• Nanoemulsion-based delivery of caffeine for skin cancer 93
• Transcutaneous electroporation for anticancer drugs 93
• Transdermal drug delivery for prostate cancer 94
• Transdermal nitroglycerine for prostate cancer 94
• Transdermal estradiol gel for prostate cancer 94
• Transdermal drug delivery for breast cancer 94
• Afimoxifene topical gel for breast cancer 94
• Pain 94
• Relief of pain associated with minor medical procedures 95
• Transdermal Lidoderm® for postherpectic neuralgia 95
• Nonsteroidal antiinflammatory drugs 95
• Topical NSAIDs 96
• Transdermal ketoprofen 97
• Topical opioids 98
• Cancer pain 98
• Transdermal fentanyl 98
• Transdermal nitroglycerine as an adjuvant to opioids 99
• Transdermal buprenorphine 99
• Chronic pain of non-malignant origin 99
• Transdermal local anesthetics 100
• Postoperative pain 100
• Transdermal fentanyl for the management of postoperative pain 100
• Fibromyalgia 101
• Nausea and vomiting 101
• Motion sickness 101
• Postoperative vomiting 101
• Chemotherapy-induced nausea and vomiting 101
• Antiaging strategies 102
• Smoking cessation 102
• Transdermal nicotine replacement 102
• Use of nicotine patch for smoking cessation in pregnancy 103
• Other methods of nicotine replacement 103
• Other treatments for smoking cessation 104
• Miscellaneous uses of transdermal drug delivery 104
• Chronic fatigue syndrome 104
• Topical androgenic steroid therapy 104
• Overactive bladder and urinary incontinence 104
• Transdermal oxybutynin 105
• Viral infections 105
• Transdermal nanoparticles for immune enhancement in HIV 105
• Transdermal gene therapy 106
• Transdermal delivery of plasmid DNA by electroporation 106
• Transdermal antisense therapy 107
• Transdermal vaccination 107
• The skin as an immune organ 108
• Technologies for transdermal vaccination 108
• Electroporation for administering DNA vaccines 108
• Intradermal delivery of cancer vaccines by adenoviral vectors 108
• Microneedles for transdermal delivery of vaccines 109
• Needle-free delivery of vaccines 110
• Transcutaneous immunization 110
• Applications of transdermal vaccination 110
• HIV/AIDS vaccination by topical application 110
• Transdermal DNA influenza vaccine 111
• Transdermal Aβ vaccination for Alzheimer's disease 111
• Transdermal vaccination for traveller's diarrhoea 112
• Transdermal neutraceuticals 112
• Complications of transdermal therapy 113
• Adverse effects of drugs 113
• Overdose effect 113
• Skin complications 113

4. Markets for Transdermal Drug Delivery 116

• Introduction 116
• Global markets for drug delivery 116
• Geographical distribution of transdermal drug delivery markets 117
• Emerging transdermal drug delivery markets in Asia 117
• Transdermal technology markets in therapeutic areas 117
• Angina pectoris 118
• Attention deficit hyperactivity disorder 118
• Erectile dysfunction 118
• Hypertension 119
• Pain therapeutics 119
• Parkinson's disease 119
• Smoking cessation 119
• Transdermal hormone replacement therapy for menopause 119
• Transdermal testosterone replacement therapy for hypogonadism in the male 120
• Transdermal contraceptive market 120
• Markets according to transdermal technologies 120
• Markets for microneedle-based transdermal drug delivery 121
• Marketing strategies for transdermal drug delivery 121
• Marketing advantages of transdermal drug delivery 121
• Unmet needs in transdermal drug delivery 122
• Future prospects of transdermal drug delivery 123
• Prospects of transdermal delivery for drugs coming off patents 123
• Transdermal delivery of cosmetics 124

5. Companies involved in transdermal drug delivery 126

• Profiles of companies 126
• Collaborations 264

6. References 268

Tables

• Table 1-1: Historical landmarks in the development of transdermal drug delivery 11
• Table 1-2: Transdermal vs oral and intravenous drug delivery 13
• Table 2-1: Technologies for transdermal drug delivery 17
• Table 2-2: Chemical enhancers of skin penetration 22
• Table 2-3: Drug-in-adhesive versus reservoir type of transdermal patch 27
• Table 2-4: Companies developing transdermal patches for drug delivery 28
• Table 2-5: Companies with technologies for drug delivery by iontophoresis 36
• Table 2-6: Companies involved in electroporation-based drug delivery 39
• Table 2-7: Companies developing microneedles for transdermal drug delivery 52
• Table 2-8: Comparison of transdermal drug delivery systems 59
• Table 3-1: Approved transdermal products 65
• Table 3-2: Transdermal drugs in clinical trials or approval process 67
• Table 4-1: Worldwide drug delivery market growth 2011 to 2021 116
• Table 4-2: Transdermal drug delivery markets for geographical regions 2011 to 2021 117
• Table 4-3: Potential therapeutic markets for transdermal products 2011-2021 118
• Table 4-4: Markets according to transdermal technologies 120
• Table 4-5: Marketing strategies based on transdermal drug delivery technologies 121
• Table 5-1: Collaborations in transdermal drug delivery 264

Figures

• Figure 1-1: Basic structure of the skin 12
• Figure 1-2: Events governing transcutaneous drug absorption 15
• Figure 2-1: Basic structure and function of transdermal drug delivery systems 27
• Figure 2-2: A schematic view of electroporation 32
• Figure 2-3: Depiction of breakdown of the stratum corneum during electroporation 33
• Figure 2-4: A schematic drawing of Iontophoresis 34
• Figure 2-5: SonoPrep ultrasonic skin permeation 42
• Figure 2-6: A schematic drawing of the microneedle patch 46
• Figure 3-1: Oral versus transdermal administration of a drug in Parkinson's disease 75
• Figure 4-1: Unmet needs in transdermal drug delivery 123

相關商品

DDS相關市場調查報告書

癌症相關之藥物傳輸：技術、市場、企業
Drug Delivery in Cancer - technologies, markets and companies
價格 : US $ 4000
出版日期 : 2012年04月

中樞神經系統相關之藥物傳輸：技術・市場・企業
Drug Delivery in Central Nervous System Diseases - technologies, markets and companies
價格 : US $ 3000
出版日期 : 2012年04月

心血管之藥物輸送：技術、市場、企業
Cardiovascular Drug Delivery - technologies,markets and companies
價格 : US $ 2800
出版日期 : 2012年04月

Jain Pharmabiotech發行的製藥相關市場調查報告書

分子診斷﹕技術˙市場˙企業

Molecular Diagnostics - Technologies, Markets and Companies

價格 : US $ 5500

出版日期 : 2012年04月

細胞治療:技術˙市場˙企業

Cell Therapy - Technologies, Markets and Companies

價格 : US $ 5500

出版日期 : 2012年04月

神經保護：醫療藥品・市場・企業

Neuroprotection - Drugs, Markets and Companies

價格 : US $ 5000

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!